What is Semaglutide?
Semaglutide is a prescription medication at the forefront of medical weight loss. Originally developed to treat type 2 diabetes, it has since been approved for chronic weight management under the brand name Wegovy. This medication belongs to a class called GLP-1 receptor agonists, which mimic a natural hormone responsible for regulating appetite and blood sugar. What sets semaglutide apart is its unique combination of metabolic effects and real-world, sustained weight loss—an outcome that has placed it at the center of a modern approach to obesity.
Unlike older weight loss medications, semaglutide was tested in rigorous, large-scale studies. In pivotal STEP clinical trials, adults prescribed Wegovy lost an average of 15% of their body weight over 68 weeks, provided they also made dietary and lifestyle changes. For many, this difference means improved health markers, greater energy, and a restored sense of control over their weight journey.
How Semaglutide Works in the Body
Semaglutide acts by activating GLP-1 receptors, which influence how your body regulates insulin, glucose, and hunger. These receptors signal the brain to decrease appetite and slow the emptying of food from the stomach, leading to earlier feelings of fullness. As a result, calorie intake drops—often without the intense cravings or fatigue associated with strict diets.
- Regulates appetite: Less frequent and less intense hunger signals.
- Stabilizes blood sugar: Particularly beneficial for those with prediabetes or type 2 diabetes.
- Slows stomach emptying: Promotes satiety and reduces overeating.
- Triggers weight loss: By addressing the root hormonal drivers of obesity.
Importantly, semaglutide is not a stimulant, nor does it act on the brain's reward pathways like older appetite suppressants. Its effects are specific, measurable, and reproducible in both research and clinical settings.
Who Should Consider Semaglutide?
Semaglutide is indicated for adults who meet one of the following:
- BMI of 30 or higher (obesity), or
- BMI of 27 or higher (overweight) with at least one weight-related medical problem, such as hypertension, high cholesterol, or type 2 diabetes.
Consultation with a qualified healthcare provider is essential. They will evaluate your full health history, answer questions about eligibility, and outline the pros and cons of semaglutide versus other obesity medication options. Early in the process, patients receive education on diet, exercise, and self-injection technique, ensuring safety and setting realistic expectations.
Dosing & Administration
Semaglutide (Wegovy) is taken as a once-weekly injection under the skin, typically in the abdomen or thigh. The dose is gradually increased over several weeks to reduce side effect risk. Most patients start at 0.25 mg and advance to the target 2.4 mg dose, following a protocol like this:
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly (maintenance)
Your healthcare provider will personalize this schedule. Adherence and proper technique are key to minimizing discomfort and maximizing benefit. For detailed recommendations, see our wegovy dosage page.
Potential Side Effects & Risks
Like all medications, semaglutide can have side effects. The most common are temporary, affecting the digestive system as your body adapts:
- Nausea (especially early on)
- Vomiting or diarrhea
- Constipation
- Abdominal discomfort
Most symptoms diminish within weeks, but ongoing issues or severe symptoms require prompt contact with your healthcare provider. Rare but serious risks include pancreatitis, gallbladder disease, and, in very rare cases, thyroid tumors. Patients are screened for risk factors before starting semaglutide, and routine follow-ups are built into treatment plans. For a thorough breakdown, read our wegovy side effects guide.
What Results Can You Expect?
In supervised studies, individuals on semaglutide achieved an average of 15% reduction in body weight, with the most significant losses occurring within the first six months. Maintenance of weight loss is possible with ongoing treatment and lifestyle changes.
- Initial results typically appear after 4-8 weeks
- Peak benefit at 6-12 months with consistent use
- Improvements in cardiovascular, metabolic, and emotional health reported by many patients
However, individual results vary. Long-term success requires partnership with your care team and a commitment to behavioral change. Stopping semaglutide often leads to weight regain, so ongoing dialogue with your provider is essential.
Semaglutide vs. Other GLP-1 Medications
Semaglutide is not the only GLP-1 agonist, but it is the first approved for chronic weight management at its current dose. Other agents, like liraglutide and dulaglutide, are often prescribed for diabetes but yield less dramatic weight loss in trials. Semaglutide's once-weekly dosing and stronger appetite control make it the preferred GLP-1 for obesity when prescribed by experts. Learn more about the GLP-1 class on our glp1 overview.
Is Semaglutide Right For You?
Choosing semaglutide is a shared decision between patient and provider. It is not for everyone, but for those who have struggled with weight regain or failed diets, it offers a new path—grounded in science, not empty promises. If you are ready to explore advanced, medically-supported weight loss, consult a doctor for a personalized assessment.
Wegovy Guide is committed to delivering transparent, up-to-date information for every stage of your weight loss journey.